BioSpace News Archive

Foundation Medicine, Inc., today announced that the company will present 11 abstracts demonstrating the value of high-quality biomarker tests to inform cancer care at the 2023 European Society for Medical Oncology (ESMO) Annual Meeting from October 20-24 in Madrid, Spain.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced that Bristol Myers Squibb (BMS) reported positive topline results from the Phase 3 CheckMate-67T trial evaluating a subcutaneous (SC) formulation of Opdivo (nivolumab) with ENHANZE® in patients with advanced or metastatic clear cell renal cell carcinoma.

BioVie Inc. today announced that blinded data on cognitive, biomarker, and imaging findings from the recently completed Phase 3 clinical trial ( NCT04669028 ) of NE3107 in the treatment of mild to moderate Alzheimer’s Disease will be presented during an oral presentation at the upcoming 16th Clinical Trials on Alzheimer’s Disease (CTAD), to be held in Boston, MA from October 24-27, 2023.

NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”) today announced an upcoming poster presentation on a final report of a Phase I dose escalation study of SNK01 in subjects with Alzheimer’s Disease, at the 16th Clinical Trials on Alzheimer’s Disease Annual Meeting to be held in Boston, MA, USA from October 24–27, 2023.

Lirum Therapeutics, Inc. announced today that Peter McDonald, the CEO of Lirum, will present at the 2023 ThinkEquity Conference on Thursday, October 19, 2023, at 2:00 PM ET.

A recent clinical publication in the Journal of Clinical Medicine (JCM) highlighted early surgical experience with Envoy Medical®, Inc.’s (“Envoy Medical”) (NASDAQ: “COCH”) investigational Acclaim® fully implantable cochlear implant.

Onconova Therapeutics, Inc. announced that one of the Company’s scientific collaborators, Gaël Roué, Ph.D., from the Josep Carreras Leukaemia Research Institute, Spain, made a podium presentation during the European MCL Network Annual Meeting in Dublin, Ireland on October 7, 2023 regarding promising ongoing preclinical studies of narazaciclib, in combination with ibrutinib and other targeted therapies used in the treatment for mantle cell lymphoma.

Gameto presented four abstracts at the 2023 American Society for Reproductive Medicine Congress.

STRM.BIO, a pre-clinical, VC-backed biotechnology company that is leveraging extracellular vesicles to deliver gene therapies and developing new therapeutics for rare blood diseases, announced that CEO Jonathan Thon, Ph.D. is the featured speaker at the 5th annual R. D. Zeigler Innovation Research Lecture Sponsored by the Versiti Blood Research Institute.

VolitionRx Limited announces the publication of a clinical paper1 which shows that Volition’s Nu.Q® NETs test is a promising biomarker for the evaluation of disease severity in septic shock patients and could play an important role in sepsis prognosis.